Payment overview · 2025
General Payments
$2,260.15
120 reported records · 33 companies
Healthcare provider profile · identity verified
Danilo Corales
Allopathic & Osteopathic Physicians|Internal Medicine · LEXINGTON, KY · NPI 1013951771
Verified facts
What the public records show
CMS Open Payments records show Danilo Corales received $2,260.15 in general payments during 2025 across 120 reported records.
Novo Nordisk Inc accounted for 16.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 44 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Edarbi, Eliquis, Gemtesa, Jardiance, Mounjaro, Ozempic, Paxlovid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DALIRESP as an associated drug or biological on 54 records involving 42 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Daliresp by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EDARBI as an associated drug or biological on 1140 records involving 805 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Edarbi by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 262 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 262 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 223 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 410 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trulance by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $380.12 | 16.8% | 16 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $280.89 | 12.4% | 17 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $219.78 | 9.7% | 12 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $203.51 | 9.0% | 14 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $100.76 | 4.5% | 6 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $94.80 | 4.2% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $92.08 | 4.1% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $76.36 | 3.4% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $62.76 | 2.8% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $61.70 | 2.7% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $61.25 | 2.7% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $60.50 | 2.7% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $59.63 | 2.6% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $55.34 | 2.5% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $55.12 | 2.4% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $43.97 | 1.9% | 2 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.93 | 1.5% | 2 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $32.84 | 1.4% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $28.24 | 1.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $25.06 | 1.1% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.82 | 1.1% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $23.29 | 1.0% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $23.09 | 1.0% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $19.98 | 0.9% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $18.71 | 0.8% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $18.04 | 0.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.31 | 0.7% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $15.90 | 0.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.83 | 0.7% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.84 | 0.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.15 | 0.6% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $13.79 | 0.6% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $13.76 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,260.15 | 120 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $280.89 | 17 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $232.28 | 13 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $225.48 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $225.48 | 8 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $168.56 | 12 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $141.35 | 7 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $107.56 | 8 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $100.76 | 6 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $98.07 | 6 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $94.80 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $92.08 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $91.51 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $76.36 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $65.15 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $62.76 | 3 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $62.70 | 3 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $61.70 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $61.00 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $60.50 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $59.63 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $55.34 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $55.12 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $43.97 | 2 | 2025 |
Source payment records
|
|||||
| EDARBI Normalized: edarbi |
Drug | Azurity Pharmaceuticals, Inc. | $33.93 | 2 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $32.84 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $31.13 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $28.24 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $27.75 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $25.06 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $23.82 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $23.09 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.98 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $18.71 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $18.04 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $17.56 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $17.39 | 1 | 2025 |
Source payment records
|
|||||
| LAGEVRIO Normalized: lagevrio |
Drug | Merck Sharp & Dohme LLC | $16.31 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $15.90 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.83 | 1 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $14.84 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.15 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.03 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $13.79 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $13.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| EDARBI edarbi |
2025 | Edarbi | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 410 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 262 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 223 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 40 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 114 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
149 | 38 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | DALIRESP open payments reported associated product |
CMS Open Payments — General Payments 54 supporting records · 42 recipient NPIs · example record 1206139572 |
Daliresp · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | EDARBI open payments reported associated product |
CMS Open Payments — General Payments 1140 supporting records · 805 recipient NPIs · example record 1242666830 |
Edarbi · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
262 | 52 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
114 | 22 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
104 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
262 | 52 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
223 | 35 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
410 | 64 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
40 | 40 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1177 | 258 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1160 | 283 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1047 | 215 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 761 | 216 |
| Trazodone Hcl | Trazodone Hcl | 724 | 144 |
| Omeprazole | Omeprazole | 673 | 159 |
| Pravastatin Sodium | Pravastatin Sodium | 627 | 171 |
| Famotidine | Famotidine | 613 | 135 |
| Donepezil Hcl | Donepezil Hcl | 589 | 86 |
| Gabapentin | Gabapentin | 552 | 110 |
| Pantoprazole Sodium | Pantoprazole Sodium | 516 | 126 |
| Losartan Potassium | Losartan Potassium | 510 | 117 |
| Duloxetine Hcl | Duloxetine Hcl | 502 | 112 |
| Ezetimibe | Ezetimibe | 501 | 140 |
| Metformin Hcl Er | Metformin Hcl | 501 | 121 |
| Furosemide | Furosemide | 495 | 116 |
| Lisinopril | Lisinopril | 453 | 100 |
| Mirtazapine | Mirtazapine | 446 | 80 |
| Eliquis | Apixaban | 410 | 64 |
| Tamsulosin Hcl | Tamsulosin Hcl | 409 | 90 |
| Quetiapine Fumarate | Quetiapine Fumarate | 407 | 45 |
| Citalopram Hbr | Citalopram Hydrobromide | 399 | 62 |
| Memantine Hcl | Memantine Hcl | 371 | 45 |
| Buspirone Hcl | Buspirone Hcl | 341 | 72 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 334 | 58 |
| Tramadol Hcl | Tramadol Hcl | 329 | 60 |
| Potassium Chloride | Potassium Chloride | 319 | 72 |
| Sertraline Hcl | Sertraline Hcl | 316 | 55 |
| Carvedilol | Carvedilol | 314 | 79 |
| Metoprolol Succinate | Metoprolol Succinate | 291 | 65 |
| Montelukast Sodium | Montelukast Sodium | 269 | 60 |
| Clopidogrel | Clopidogrel Bisulfate | 267 | 53 |
| Doxazosin Mesylate | Doxazosin Mesylate | 267 | 71 |
| Celecoxib | Celecoxib | 264 | 68 |
| Zolpidem Tartrate | Zolpidem Tartrate | 264 | 50 |
| Fluticasone Propionate | Fluticasone Propionate | 262 | 76 |
| Jardiance | Empagliflozin | 262 | 52 |
| Metoprolol Tartrate | Metoprolol Tartrate | 245 | 57 |
| Tizanidine Hcl | Tizanidine Hcl | 240 | 59 |
| Simvastatin | Simvastatin | 239 | 50 |
| Alprazolam | Alprazolam | 233 | 52 |
| Ozempic | Semaglutide | 223 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 218 | 56 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 218 | 51 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 214 | 48 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 206 | 65 |
| Escitalopram Oxalate | Escitalopram Oxalate | 204 | 45 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 202 | 54 |
| Bupropion Xl | Bupropion Hcl | 191 | 45 |
| Aripiprazole | Aripiprazole | 188 | 27 |
| Allopurinol | Allopurinol | 186 | 55 |
| Glimepiride | Glimepiride | 165 | 41 |
| Synthroid | Levothyroxine Sodium | 149 | 38 |
| Doxycycline Hyclate | Doxycycline Hyclate | 144 | 115 |
| Hydrochlorothiazide | Hydrochlorothiazide | 142 | 36 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 139 | 28 |
| Metformin Hcl | Metformin Hcl | 134 | 31 |
| Clonazepam | Clonazepam | 123 | 21 |
| Nebivolol Hcl | Nebivolol Hcl | 123 | 31 |
| Myrbetriq | Mirabegron | 122 | 28 |
| Azithromycin | Azithromycin | 120 | 105 |
| Cefdinir | Cefdinir | 120 | 93 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 116 | 36 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 114 | 22 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 113 | 17 |
| Pregabalin | Pregabalin | 112 | 21 |
| Doxepin Hcl | Doxepin Hcl | 111 | 26 |
| Bumetanide | Bumetanide | 108 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 106 | 28 |
| Xarelto | Rivaroxaban | 104 | 22 |
| Propranolol Hcl | Propranolol Hcl | 103 | 23 |
| Paroxetine Hcl | Paroxetine Hcl | 102 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 96 | 30 |
| Divalproex Sodium | Divalproex Sodium | 95 | 17 |
| Ondansetron Odt | Ondansetron | 90 | 46 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 88 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 85 | 46 |
| Prednisone | Prednisone | 82 | 32 |
| Atenolol | Atenolol | 81 | 14 |
| Diazepam | Diazepam | 79 | 11 |
| Mupirocin | Mupirocin | 79 | 52 |
| Alendronate Sodium | Alendronate Sodium | 78 | 22 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 76 | 27 |
| Warfarin Sodium | Warfarin Sodium | 75 | 14 |
| Meloxicam | Meloxicam | 72 | 30 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 70 | 24 |
| Spironolactone | Spironolactone | 70 | 20 |
| Temazepam | Temazepam | 70 | 11 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 69 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 69 | 21 |
| Promethazine Hcl | Promethazine Hcl | 68 | 14 |
| Irbesartan | Irbesartan | 67 | 17 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 67 | 22 |
| Ipratropium Bromide | Ipratropium Bromide | 65 | 17 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 65 | 13 |
| Chlorthalidone | Chlorthalidone | 64 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 64 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 63 | 12 |
| Acyclovir | Acyclovir | 61 | 17 |
| Topiramate | Topiramate | 61 | suppressed |
| Levetiracetam | Levetiracetam | 59 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 59 | 15 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 58 | 17 |
| Ketoconazole | Ketoconazole | 56 | 21 |
| Baclofen | Baclofen | 55 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 55 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 53 | 28 |
| Entresto | Sacubitril/Valsartan | 51 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 50 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 49 | 17 |
| Valsartan | Valsartan | 49 | 14 |
| Clonidine Hcl | Clonidine Hcl | 46 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 43 | 12 |
| Methenamine Hippurate | Methenamine Hippurate | 43 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 42 | suppressed |
| Mounjaro | Tirzepatide | 42 | suppressed |
| Nitroglycerin | Nitroglycerin | 42 | 24 |
| Colchicine | Colchicine | 41 | 17 |
| Olanzapine | Olanzapine | 41 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 40 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 40 | 15 |
| Fentanyl | Fentanyl | 40 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 40 | 40 |
| Trulicity | Dulaglutide | 40 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 40 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 38 | suppressed |
| Cephalexin | Cephalexin | 38 | 32 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 38 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 37 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | 12 |
| Mometasone Furoate | Mometasone Furoate | 37 | 14 |
| Metolazone | Metolazone | 36 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 36 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 36 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 32 |
| Finasteride | Finasteride | 35 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 34 | suppressed |
| Amoxicillin | Amoxicillin | 34 | 29 |
| Benztropine Mesylate | Benztropine Mesylate | 34 | suppressed |
| Nystatin | Nystatin | 34 | 27 |
| Propranolol Hcl Er | Propranolol Hcl | 34 | suppressed |
| Nateglinide | Nateglinide | 33 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 33 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 32 | 12 |
| Lansoprazole | Lansoprazole | 32 | 11 |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Glipizide Er | Glipizide | 31 | suppressed |
| Nifedipine Er | Nifedipine | 31 | suppressed |
| Primidone | Primidone | 31 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 31 | suppressed |
| Latanoprost | Latanoprost | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | 16 |
| Amiodarone Hcl | Amiodarone Hcl | 29 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 29 | 16 |
| Lactulose | Lactulose | 29 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 28 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 28 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 28 | 12 |
| Risperidone | Risperidone | 28 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Carisoprodol | Carisoprodol | 27 | suppressed |
| Fluconazole | Fluconazole | 27 | 23 |
| Glyxambi | Empagliflozin/Linagliptin | 27 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 27 | 27 |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 26 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 25 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 25 | suppressed |
| Gemtesa | Vibegron | 24 | suppressed |
| Lorazepam | Lorazepam | 24 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 24 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 23 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 22 | suppressed |
| Telmisartan | Telmisartan | 22 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Repatha Sureclick | Evolocumab | 21 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 20 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 20 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 20 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 20 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Torsemide | Torsemide | 19 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Acetazolamide | Acetazolamide | 16 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 16 | suppressed |
| Erythromycin | Erythromycin Base | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Cilostazol | Cilostazol | 15 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 13 |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Amantadine | Amantadine Hcl | 14 | suppressed |
| Carbamazepine Er | Carbamazepine | 14 | suppressed |
| Edarbi | Azilsartan Medoxomil | 14 | suppressed |
| Felodipine Er | Felodipine | 14 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Restasis | Cyclosporine | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Trulance | Plecanatide | 14 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Etodolac | Etodolac | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Nabumetone | Nabumetone | 13 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 13 | suppressed |
| Tirosint | Levothyroxine Sodium | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Budesonide Ec | Budesonide | 12 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 12 | suppressed |
| Cimetidine | Cimetidine | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Famciclovir | Famciclovir | 12 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 12 | suppressed |
| Humulin R | Insulin Regular, Human | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Nadolol | Nadolol | 12 | suppressed |
| Oxazepam | Oxazepam | 12 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Daliresp | Roflumilast | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,260.15 · 120 records | Novo Nordisk Inc | AIRSUPRA, AREXVY, Auvelity, CAPLYTA, Cologuard Collection Kit, EDARBI, ELIQUIS, FANAPT, FREESTYLE LIBRE 3, GEMTESA, GVOKE HYPOPEN, HETLIOZ, Heplisav-B, IBSRELA, JARDIANCE, KISUNLA, Korlym, LAGEVRIO, LEQVIO, MOUNJARO, NURTEC ODT, ONPATTRO, OTEZLA, Ohtuvayre, Omnipod, Ozempic, PAXLOVID, QULIPTA, REPATHA, REXULTI, Rybelsus, SPRAVATO, TONMYA, TRELEGY ELLIPTA, TZIELD, UBRELVY, VOQUEZNA, VYNDAMAX, WATCHMAN Access System, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND, ZORYVE | 19 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Edarbi play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error